Last reviewed · How we verify
NCT05193656: BLAInostic
Bladder Cancer Detection Using Convolutional Neural Networks
trial testing Al_bladder in Bladder Cancer in 5,000 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Zealand University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 June 2021 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Al_bladder
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
Zealand University Hospital
Who can join
Eligibility, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aim to experiment and implement various deep learning architectures to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems. In particular, the investigators are interested in detecting bladder tumors from CT urography scans and cystoscopies of the bladder in this project.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in Liquid Biopsy for Diagnosis of Bladder Cancer.
Seok J, Kwak Y, Kim S, Kim EM, et al · · 2024 · cited 6× · PMID 38956768 · DOI 10.5213/inj.2448198.099
Verify or expand the search:
- PubMed search for NCT05193656
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other Zealand University Hospital trials
Trials by the same sponsor.
- NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
- NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
- NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
- NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
- NCT07365527 — Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05193656 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
- Last refreshed: 30 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05193656.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing